Multiplex brain proteomic analysis revealed the molecular therapeutic effects of Buyang Huanwu Decoction on cerebral ischemic stroke mice
Journal
PLoS ONE
Journal Volume
10
Journal Issue
10
Date Issued
2015
Author(s)
Abstract
Stroke is the second-leading cause of death worldwide, and tissue plasminogen activator (TPA) is the only drug used for a limited group of stroke patients in the acute phase. Buyang Huanwu Decoction (BHD), a traditional Chinese medicine prescription, has long been used for improving neurological functional recovery in stroke. In this study, we characterized the therapeutic effect of TPA and BHD in a cerebral ischemia/reperfusion (CIR) injury mouse model using multiplex proteomics approach. After the iTRAQ-based proteomics analysis, 1310 proteins were identified from the mouse brain with <1% false discovery rate. Among them, 877 quantitative proteins, 10.26% (90/877), 1.71% (15/877), and 2.62% (23/877) of the proteins was significantly changed in the CIR, BHD treatment, and TPA treatment, respectively. Functional categorization analysis showed that BHD treatment preserved the integrity of the blood-brain barrier (BBB) (Alb, Fga, and Trf), suppressed excitotoxicity (Grm5, Gnai, and Gdi), and enhanced energy metabolism (Bdh), thereby revealing its multiple effects on ischemic stroke mice. Moreover, the neurogenesis marker doublecortin was upregulated, and the activity of glycogen synthase kinase 3 (GSK-3) and Tau was inhibited, which represented the neuroprotective effects. However, TPA treatment deteriorated BBB breakdown. This study highlights the potential of BHD in clinical applications for ischemic stroke. ? 2015 Chen et al This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
SDGs
Other Subjects
adenosine triphosphatase; adenosine triphosphatase regulatory subunit 7; adenosine triphosphatase regulatory subunit 8; albumin; amino acid transfer RNA ligase; buyang huanwu; carrier protein; catalase; clusterin; complement component C3; diazepam binding inhibitor; dihydropyrimidinase; dihydropyrimidinase 3; dihydropyrimidinase 5; doublecortin; excitatory amino acid transporter 2; fibrinogen; glial fibrillary acidic protein; glutamyl prolyl transfer RNA ligase; glycogen synthase kinase 3; plant medicinal product; Slc30a3 protein; soluble n ethylmaleimide sensitive factor attachment protein; soluble n ethylmaleimide sensitive factor attachment protein alpha; tau protein; tissue plasminogen activator; transferrin; transportin 2; unclassified drug; unindexed drug; zinc transporter; buyang huanwu; herbaceous agent; animal experiment; animal model; apoptosis; Article; blood brain barrier; brain ischemia; controlled study; drug efficacy; drug mechanism; drug targeting; energy metabolism; enzyme activity; male; mouse; neuroprotection; nonhuman; protein analysis; protein content; protein expression; protein phosphorylation; treatment response; upregulation; animal; brain; brain ischemia; immunohistochemistry; Institute for Cancer Research mouse; metabolism; positron emission tomography; procedures; proteomics; Stroke; Western blotting; Animals; Blotting, Western; Brain; Brain Ischemia; Drugs, Chinese Herbal; Immunohistochemistry; Male; Mice; Mice, Inbred ICR; Positron-Emission Tomography; Proteomics; Stroke
Type
journal article
File(s)![Thumbnail Image]()
Loading...
Name
journal.pone.0140823 (1).PDF
Size
3.13 MB
Format
Adobe PDF
Checksum
(MD5):6f8fc6bf7884950735a25f2295fabbb7